U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07177118) titled 'Risankizumab for Fibrostenotic Crohn's Disease Treatment' on Sept. 05.
Brief Summary: This study, titled "IL-23 Inhibitor Ustekinumab for the Treatment of Fibrotic Crohn's Disease: A Prospective, Open-Label, Randomized Controlled Study," is conducted by researchers from the First Affiliated Hospital of Wenzhou Medical University. The primary aim of this research is to evaluate the efficacy and safety of ustekinumab, an IL-23 inhibitor, for patients with fibrostenotic Crohn's disease (CD) who have failed standard treatments.
The study is a prospective, open-label, randomized controlled trial involving 260 participants across three ...